BioRegenx, Inc.
BRGX
$0.0129
$0.001917.27%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 596.00K | 734.00K | 549.50K | -2.71M | 794.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 596.00K | 734.00K | 549.50K | -2.71M | 794.50K |
| Cost of Revenue | 114.40K | 264.20K | 165.40K | -699.60K | 223.30K |
| Gross Profit | 481.60K | 469.90K | 384.20K | -2.01M | 571.20K |
| SG&A Expenses | 246.90K | 947.60K | 2.97M | -2.78M | 3.04M |
| Depreciation & Amortization | 562.10K | 562.10K | 497.80K | 5.90K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 923.30K | 1.77M | 3.63M | -3.47M | 3.26M |
| Operating Income | -327.30K | -1.04M | -3.08M | 760.70K | -2.47M |
| Income Before Tax | -394.90K | -1.11M | -3.15M | 445.20K | -2.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -394.90K | -1.11M | -3.15M | 445.20K | -2.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -394.90K | -1.11M | -3.15M | 445.20K | -2.52M |
| EBIT | -327.30K | -1.04M | -3.08M | 760.70K | -2.47M |
| EBITDA | 247.20K | -169.60K | -2.88M | 761.90K | -2.47M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 956.53M | 956.53M | 956.53M | 989.07M | 621.92M |
| Average Diluted Shares Outstanding | 956.53M | 956.53M | 956.53M | 989.07M | 621.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
